Cann Group
Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, and distribution/supply of medicinal cannabis for a range of diseases and medical conditions in Australia. The last earnings update was 96 days ago. More info.
Add to Portfolio Compare Print
- Cann Group has significant price volatility in the past 3 months.
CAN Share Price and Events
7 Day Returns
1 Year Returns
CAN Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Cann Group (CAN) | -2.2% | -7.4% | 26.9% | -36.4% | - | - |
| AU Pharmaceuticals | 2% | -4.8% | 0.4% | -26.2% | -40.3% | -25.1% |
| AU Market | 2.5% | 2.4% | 4.8% | 5% | 19.3% | 8.7% |
1 Year Return vs Industry and Market
- CAN underperformed the Pharmaceuticals industry which returned -26.2% over the past year.
- CAN underperformed the Market in Australia which returned 5% over the past year.
Value
Is Cann Group undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Cann Group
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Cann Group.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 1 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 7.1% |
| Perpetual Growth Rate | 10-Year AU Government Bond Rate | 2.3% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year AU Govt Bond Rate | 2.3% |
| Equity Risk Premium | S&P Global | 6% |
| Pharmaceuticals Unlevered Beta | Simply Wall St/ S&P Global | 0.69 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.693 (1 + (1- 30%) (0.01%)) |
0.795 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.8 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (0.8 * 5.96%) |
7.08% |
Discounted Cash Flow Calculation for ASX:CAN using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Cann Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (AUD, Millions) | Source |
Present Value Discounted (@ 7.08%) |
|
|---|---|---|---|
| 2019 | -30.50 | Analyst x1 | -28.48 |
| 2020 | -64.60 | Analyst x1 | -56.34 |
| 2021 | -52.60 | Analyst x1 | -42.84 |
| 2022 | 20.90 | Analyst x1 | 15.90 |
| 2023 | 57.60 | Analyst x1 | 40.91 |
| 2024 | 94.29 | Est @ 63.7% | 62.55 |
| 2025 | 136.99 | Est @ 45.29% | 84.87 |
| 2026 | 181.37 | Est @ 32.39% | 104.93 |
| 2027 | 223.76 | Est @ 23.37% | 120.89 |
| 2028 | 261.91 | Est @ 17.05% | 132.15 |
| Present value of next 10 years cash flows | A$434.54 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= A$261.91 × (1 + 2.31%) ÷ (7.08% – 2.31%) |
A$5,620.13 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= A$5,620.13 ÷ (1 + 7.08%)10 |
A$2,835.71 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= A$434.54 + A$2,835.71 |
A$3,270.26 |
| Equity Value per Share (AUD) |
= Total value / Shares Outstanding
= A$3,270.26 / 139.80 |
A$23.39 |
| Calculation | Result | |
|---|---|---|
| Value per share (AUD) | From above. | A$23.39 |
| Current discount | Discount to share price of
A$2.24
= -1 x (A$2.24 - A$23.39) / A$23.39 |
90.4% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Cann Group's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Cann Group's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Cann Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Cann Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in AUD | A$-0.06 |
| ASX:CAN Share Price ** | ASX (2019-05-24) in AUD | A$2.24 |
| Australia Pharmaceuticals Industry PE Ratio | Median Figure of 6 Publicly-Listed Pharmaceuticals Companies | 20.33x |
| Australia Market PE Ratio | Median Figure of 542 Publicly-Listed Companies | 16.39x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Cann Group.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ASX:CAN Share Price ÷ EPS (both in AUD) = 2.24 ÷ -0.06 |
-38.34x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Cann Group is loss making, we can't compare its value to the AU Pharmaceuticals industry average.
- Cann Group is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does
Cann Group's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -38.34x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts |
66.1%per year |
| Global Pharmaceuticals Industry PEG Ratio | Median Figure of 117 Publicly-Listed Pharmaceuticals Companies | 1.55x |
| Australia Market PEG Ratio | Median Figure of 358 Publicly-Listed Companies | 1.43x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Cann Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Cann Group's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in AUD | A$0.59 |
| ASX:CAN Share Price * | ASX (2019-05-24) in AUD | A$2.24 |
| Australia Pharmaceuticals Industry PB Ratio | Median Figure of 26 Publicly-Listed Pharmaceuticals Companies | 3.26x |
| Australia Market PB Ratio | Median Figure of 1,680 Publicly-Listed Companies | 1.66x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ASX:CAN Share Price ÷ Book Value per Share (both in AUD) = 2.24 ÷ 0.59 |
3.82x |
* Primary Listing of Cann Group.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Cann Group is overvalued based on assets compared to the AU Pharmaceuticals industry average.
Value checks
We assess Cann Group's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check) Cann Group has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
How is Cann Group expected to perform in the next 1 to 3 years based on estimates from 1 analyst?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Cann Group's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
- Cann Group's earnings growth is expected to exceed the Australia market average.
- Cann Group's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ASX:CAN Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts | 66.1% |
| ASX:CAN Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts | 61.8% |
| Australia Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 51.4% |
| Australia Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 32.1% |
| Australia Market Earnings Growth Rate | Market Cap Weighted Average | 6.9% |
| Australia Market Revenue Growth Rate | Market Cap Weighted Average | 3.2% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-06-30 | 190 | 56 | 54 | 1 |
| 2022-06-30 | 159 | 42 | 36 | 1 |
| 2021-06-30 | 101 | -15 | 11 | 1 |
| 2020-06-30 | 4 | -22 | -18 | 1 |
| 2019-06-30 | 3 | -12 | -10 | 1 |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 2 | -7 | -8 |
| 2018-09-30 | 2 | -5 | -6 |
| 2018-06-30 | 2 | -4 | -5 |
| 2018-03-31 | 1 | -3 | -4 |
| 2017-12-31 | 0 | -2 | -3 |
| 2017-09-30 | 0 | -2 | -3 |
| 2017-06-30 | 0 | -2 | -3 |
| 2016-06-30 | 0 | -1 | -1 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
All data from Cann Group Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-06-30 | 0.38 | 0.38 | 0.38 | 1.00 |
| 2022-06-30 | 0.25 | 0.25 | 0.25 | 1.00 |
| 2021-06-30 | 0.08 | 0.08 | 0.08 | 1.00 |
| 2020-06-30 | -0.13 | -0.13 | -0.13 | 1.00 |
| 2019-06-30 | -0.07 | -0.07 | -0.07 | 1.00 |
| Date (Data in AUD Millions) | EPS * |
|---|---|
| 2018-12-31 | -0.06 |
| 2018-09-30 | -0.05 |
| 2018-06-30 | -0.04 |
| 2018-03-31 | -0.04 |
| 2017-12-31 | -0.04 |
| 2017-09-30 | -0.04 |
| 2017-06-30 | -0.05 |
| 2016-06-30 | -0.05 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Cann Group's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Cann Group has a total score of 6/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Cann Group performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Cann Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Cann Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Cann Group's 1-year growth to the Global Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
All data from Cann Group Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 1.55 | -8.16 | 10.94 | 1.25 |
| 2018-09-30 | 1.53 | -6.44 | 9.11 | 1.01 |
| 2018-06-30 | 1.50 | -4.73 | 7.29 | 0.78 |
| 2018-03-31 | 0.78 | -3.93 | 4.83 | 0.61 |
| 2017-12-31 | 0.05 | -3.13 | 2.46 | 0.47 |
| 2017-09-30 | 0.03 | -2.86 | 2.05 | 0.51 |
| 2017-06-30 | 0.01 | -2.59 | 1.64 | 0.55 |
| 2016-06-30 | 0.01 | -1.46 | 1.10 | 0.35 |
| 2015-06-30 | 0.01 | -4.18 | 3.67 | 0.44 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Cann Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Cann Group has efficiently used its assets last year compared to the AU Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Cann Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Cann Group's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Cann Group has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Cann Group's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Cann Group's finances.
The net worth of a company is the difference between its assets and liabilities.
- Cann Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Cann Group's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 4097.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Cann Group Company Filings, last reported 4 months ago.
| Date (Data in AUD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 81.98 | 0.02 | 72.56 |
| 2018-09-30 | 81.98 | 0.02 | 72.56 |
| 2018-06-30 | 85.87 | 0.02 | 79.65 |
| 2018-03-31 | 85.87 | 0.02 | 79.65 |
| 2017-12-31 | 69.57 | 0.02 | 66.52 |
| 2017-09-30 | 69.57 | 0.02 | 66.52 |
| 2017-06-30 | 14.66 | 0.02 | 11.11 |
| 2016-06-30 | 1.69 | 0.00 | 1.34 |
| 2015-06-30 | 0.65 | 0.00 | 0.45 |
- Cann Group's level of debt (0%) compared to net worth is satisfactory (less than 40%).
- Unable to establish if Cann Group's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Cann Group has sufficient cash runway for more than 3 years based on current free cash flow.
- Cann Group has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 70.2% each year.
Financial health checks
We assess Cann Group's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Cann Group has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Cann Group's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
A$2,000 of
Cann Group
shares you are expected to receive
A$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Cann Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Cann Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| Global Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 144 Stocks | 2.9% |
| Australia Market Average Dividend Yield | Market Cap Weighted Average of 414 Stocks | 4.2% |
| Australia Minimum Threshold Dividend Yield | 10th Percentile | 1.5% |
| Australia Bottom 25% Dividend Yield | 25th Percentile | 2.6% |
| Australia Top 25% Dividend Yield | 75th Percentile | 5.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in A$) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-06-30 | ||
| 2022-06-30 | ||
| 2021-06-30 | ||
| 2020-06-30 | ||
| 2019-06-30 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Cann Group has not reported any payouts.
- Unable to verify if Cann Group's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Cann Group's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Cann Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Cann Group has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | A$993,626 |
| TENURE AS CEO | 3 years |
CEO Bio
Mr. Peter Crock, B.Ag.Sci (Hons), MBA has been Chief Executive Officer at CANN Group Limited since May 23, 2016. Mr. Crock is an experienced public company senior manager with strong skills in marketing and technology development. In a 28 year career at Nufarm Limited, he held senior management roles in marketing, business development and information technology, heading up its new technologies division which involved the licensing and commercial development of several new agribusiness technologies. He has project managed the successful integration of newly acquired businesses and has extensive experience working with regulators in Australia and overseas.
CEO Compensation
- Peter's compensation has increased whilst company is loss making.
- Peter's remuneration is higher than average for companies of similar size in Australia.
Management Team
Peter Crock
Chief Executive Officer
A$994K
3 yrs
Richard Baker
Company Secretary & CFO
Steven Notaro
Legal and Regulatory Affairs Officer
Board of Directors Tenure
Average tenure of the Cann Group board of directors in years:
- The tenure for the Cann Group board of directors is about average.
Board of Directors
Allan McCallum
Non-Executive Chairman
A$33K
Philip Robert Jacobsen
Deputy Chairman
A$22K
Doug Rathbone
Independent Non-Executive Director
A$22K
72
4.2 yrs
Geoff Pearce
Independent Non-Executive Director
A$22K
3.1 yrs
Neil Belot
Non-Executive Director
A$7K
1.3 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (A$) | Value (A$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 23. Dec 18 | Buy | Philip Robert Jacobsen | Individual | 20. Dec 18 | 20. Dec 18 | 10,000 | A$1.83 | A$18,291 | ||
| 18. Dec 18 | Buy | Philip Robert Jacobsen | Individual | 14. Dec 18 | 18. Dec 18 | 20,000 | A$2.06 | A$41,242 | ||
Management checks
We assess Cann Group's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Cann Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
What Kind Of Investor Owns Most Of Cann Group Limited (ASX:CAN)?
Every investor in Cann Group Limited (ASX:CAN) should be aware of the most powerful shareholder groups. … Cann Group is not a large company by global standards. … Taking a look at our data on the ownership groups (below), it's seems that.
Simply Wall St - – Full articleImagine Owning Cann Group (ASX:CAN) And Wondering If The 40% Share Price Slide Is Justified
Cann Group isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … When a company doesn't make profits, we'd generally expect to see good revenue growth. … Cann Group grew its revenue by 2842% over the last year.
Simply Wall St - – Full articleDid Cann Group Limited (ASX:CAN) Insiders Buy Up More Shares?
So we'll take a look at whether insiders have been buying or selling shares in Cann Group Limited (ASX:CAN). … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Cann Group Insider Transactions Over The Last Year.
Simply Wall St - – Full articleThese Factors Make Cann Group Limited (ASX:CAN) An Interesting Investment
Cann Group Limited (ASX:CAN) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … In the case of CAN, it
Simply Wall St - – Full articleCann Group Limited (ASX:CAN) Is Expected To Breakeven
Cann Group Limited's (ASX:CAN):. … Cann Group Limited, an agribusiness company, focuses on breeding, cultivating, manufacturing, and selling medicinal cannabis for a range of diseases and medical conditions in Australia. … With the latest financial year loss of -AU$2.59m and a trailing-twelve month of -AU$3.13m, the AU$396.79m market-cap amplifies its loss by moving further away from its breakeven target.
Simply Wall St - – Full articleWhen Will Cann Group Limited (ASX:CAN) Become Profitable?
I’ve put together a brief outline of industry analyst expectations for CAN, its year of breakeven and its implied growth rate. … ASX:CAN Past Future Earnings May 15th 18 Underlying developments driving CAN’s growth isn’t the focus of this broad overview, however, bear in mind that by and large a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. … So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
Simply Wall St - – Full articleCann Group Limited (ASX:CAN): How Much Growth Is Left In Healthcare?
Not surprisingly, this rate is more than double the growth rate of the Australian stock market as a whole. … ASX:CAN PE PEG Gauge Nov 30th 17 The pharmaceutical sector's PE is currently hovering around 24x, above the broader Australian stock market PE of 17x. … Although its growth has delivered lower growth relative to its pharmaceutical peers in the near term, the market may be pessimistic on the stock, leading to a potential undervaluation.
Simply Wall St - – Full articleDoes Cann Group Limited's (ASX:CAN) CEO Pay Reflect Performance?
View our latest analysis for Cann Group What has been the trend in CAN's earnings? … Normally I'd use market cap and profit as factors determining performance, however, CAN's negative earnings reduces the effectiveness of this method. … To find out more about CAN's governance, look through our infographic report of the company's board and management.
Simply Wall St - – Full articleHas Cann Group Limited (ASX:CAN) Got Enough Cash To Cover Its Short-Term Obligations?
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Cann Group Limited (ASX:CAN), as the company does not have to adhere to strict debt covenants. … Check out our latest analysis for Cann Group Is financial flexibility worth the lower cost of capital? … Choosing financial flexibility over capital returns make sense if CAN is a high-growth company.
Simply Wall St - – Full articleCompany Info
Description
Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, and distribution/supply of medicinal cannabis for a range of diseases and medical conditions in Australia. The company was founded in 2015 and is headquartered in Bundoora, Australia.
Details
| Name: | Cann Group Limited |
| CAN | |
| Exchange: | ASX |
| Founded: | 2015 |
| A$311,763,470 | |
| 139,804,247 | |
| Website: | http://www.canngrouplimited.com |
| Address: |
Cann Group Limited Walter and Eliza Hall Institute of Medical Research, 4 Research Avenue, Bundoora, Victoria, 3083, Australia |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ASX | CAN | Ordinary Shares | Australian Securities Exchange | AU | AUD | 04. May 2017 | |
| OTCPK | CNGG.F | Ordinary Shares | Pink Sheets LLC | US | USD | 04. May 2017 | |
| DB | CVJ | Ordinary Shares | Deutsche Boerse AG | DE | EUR | 04. May 2017 |
Number of employees
Current staff
Industry
| Pharmaceuticals | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/24 10:36 |
| End of day share price update: | 2019/05/24 00:00 |
| Last estimates confirmation: | 2019/04/09 |
| Last earnings filing: | 2019/02/17 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
